Boston Scientific earnings loom with cyberattack impact on deck
Boston Scientific (BSX) reports Q3 earnings on Wednesday, with analysts expecting $0.75 EPS on $5.12B revenue, down from Q2. An August cyberattack disrupted operations, leading to lowered guidance and a 10% cut in revenue projections. Despite near-term challenges, 24 of 30 analysts rate the stock a Buy with a $57.82 price target. Competitive pressure on its Watchman device adds to uncertainties.
How this was made
The 30-second read
Why it matters
The guidance downgrade reflects a ~10% revenue reduction across divisions, increasing short‑term risk for the stock.
Market read
First report of revised Q3 guidance for a mid‑cap healthcare stock, introducing new downside risk.
What to watch
Potential upside from competitive pressure on Abbott's Watchman device may be muted by the cyber incident.
Background
Boston Scientific disclosed a major August cyberattack that disrupted manufacturing and order processing, prompting a revision of its Q3 outlook.
Ticker impact
Boston Scientific (BSX) forecasts Q3 EPS of $0.75 on $5.12B revenue after a cyberattack forced it to cut guidance.
likely pressure as investors price in lower revenue and earnings
Guidance is materially below prior expectations and the cyber incident adds uncertainty.
Market effects
Medical device sector may see broader risk reassessment for cyber‑exposure.
U.S. healthcare stocks could face modest pullback ahead of earnings season.
Limited to investors tracking U.S. med‑tech equities.
Counterpoint
If the cyberattack impact is short‑lived, the stock could rebound on a beat in Q4 guidance.
Key entities
- CompanyBoston Scientific Corp.
Medical device maker reporting Q3 earnings guidance.
- CompanyAbbott Laboratories
Competitor mentioned for its Watchman device.
